Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria
Clinical & Experimental Allergy · 2024
DOI: 10.1111/cea.14462 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Allergy, 2024. Verfasst von L Zubiaga-Fernandez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Department, Allergy Unit, Hospital Regional Universitario de Malaga and Instituto de Investigacion Biomedica de Malaga (IBIMA)-Plataforma BIO…. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Biomarkers, Anti-Allergic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, Novartis Pharmaceuticals Corporation, Consejería de Salud y Bienestar Social, Junta de Andalucía.
Abstract (Originalsprache)
Background
Clinical trials showed the efficacy of 300 mg/4 weeks of omalizumab (OMA) during 6 months in patients with severe chronic spontaneous urticaria (CSU). Nevertheless, in real life, many patients require higher doses and/or longer treatment. This study assesses the real‐life performance of OMA in severe CSU and identifies factors associated with the response.
Methods
CSU patients eligible for OMA were recruited prospectively. Clinical data and a blood test were collected before OMA initiation. Urticaria Activity Score 7 (UAS7) was calculated at baseline and every 3 months during OMA treatment. CSU control was defined as UAS7 300 mg/4 weeks. A blood basophil count >20 cells/μL (OR 13.33; 95% CI 3.32–52.63; p < .001) and the absence of hypothyroidism (OR 3.65; 95% CI 0.78–16.95; p = .099) were identified as predictive factors to achieve control with 300 mg/4 weeks. Twelve patients were able to stop OMA during the study (responders in remission, RR). RR had received OMA for a median of 29 months (12–53 months). Conversely, 32 patients had been on OMA for >29 months at the end of the study (active responders, AR). AR had received OMA for a median of 45 months (30–100 months). There were no significant differences in clinical or analytical factors between RR and AR patients.
Conclusions
Low blood basophil count and the presence of hypothyroidism might serve as biomarkers for the controller dose of OMA in severe CSU patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Department, Allergy Unit, Hospital Regional Universitario de Malaga and Instituto de Investigacion Biomedica de Malaga (IBIMA)-Plataforma BIONAND, Malaga, Spain.
- RICORS de Enfermedades Inflamatorias (ISCIII), Madrid, Spain.
- Pulmonology Department, Allergy Section, Hospital Clinic and IDIBAPS, Barcelona, Spain.
- Department of Allergy, Clinica Universidad de Navarra, Pamplona, Spain.
- Department of Medicine and Dermatology, Universidad de Malaga, Malaga, Spain.
ORCID-Profile: C Rondon, M Ferrer, I Eguiluz-Gracia
Förderung
- Instituto de Salud Carlos III
- Novartis Pharmaceuticals Corporation
- Consejería de Salud y Bienestar Social, Junta de Andalucía
Zitieren
APA
Zubiaga-Fernandez, L., Testera-Montes, A., Rondon, C., Perez-Sanchez, N., Gomez-Perez, F., Vega-Chicote, J. M., Bartra, J., Ferrer, M., Eguiluz-Gracia, I., & Torres, M. J. (2024). Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14462
Vancouver
Zubiaga-Fernandez L, Testera-Montes A, Rondon C, Perez-Sanchez N, Gomez-Perez F, Vega-Chicote JM, et al. Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria. Clinical & Experimental Allergy. 2024. doi:10.1111/cea.14462
BibTeX
@article{ZubiagaFernandez2024,
author = {Zubiaga-Fernandez, L and Testera-Montes, A and Rondon, C and Perez-Sanchez, N and Gomez-Perez, F and Vega-Chicote, J M and Bartra, J and Ferrer, M and Eguiluz-Gracia, I and Torres, M J},
title = {Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria},
journal = {Clinical & Experimental Allergy},
year = {2024},
doi = {10.1111/cea.14462}
}
EUVIMED